In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis
- 56 Downloads
Purpose of Review
To summarize our most current understanding of the real world risk of infections associated with biologic and small molecule therapies in the setting of psoriatic disease.
Patients with psoriasis or psoriatic arthritis are at increased risk for infection from both their disease and some of their therapies. There is little real world data for biologic and small molecule therapies; however, ustekinumab and biologics inhibiting IL-17 or IL-23 appear to have reduced risk estimates compared to anti-TNF therapies. Apremilast seems to have little infectious signal with limited real world data, and for JAK inhibitors, limited real world data suggest a higher risk of herpes zoster.
Recently approved targeted and small molecule therapies for psoriasis carry infectious risks for patients, although they appear to vary across mechanism of action. As these treatments become more widespread, and additional therapies are approved, it will be imperative to evaluate their safety in the context of real world data.
KeywordsPsA PsO Opportunistic infection Biologics Serious infections
Compliance with Ethical Standards
Conflict of Interest
Sarah Siegel has no conflicts of interest. Dr. Winthrop reports grants and personal fees from Pfizer, grants and personal fees from BMS, personal fees from AbbVie, personal fees from UCB, personal fees from Lilly, personal fees from Galapagos, personal fees from GSK, personal fees from Roche, and personal fees from Gilead, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2018.Google Scholar
- 11.Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1. Expert Rev Dermatol. 2007;2:69–78.Google Scholar
- 16.•• Takeshita J, Shin DB, Ogdie A, Gelfand JM. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J Invest Dermatol. 2018;138(8):1726–35 This is one of the first studies that identifies psoriasis severity, as measured by BSA, as contributing to risk of serious infection independent of other risk factors associated with psoriasis.PubMedGoogle Scholar
- 19.Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11(10):1210–7.PubMedGoogle Scholar
- 23.Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gómez-García FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29(5):858–64.PubMedGoogle Scholar
- 24.• Yiu ZZN, Smith CH, Ashcroft DM, et al. Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138(3):534–41 This study is one of the best examples from a pharmacoepidemiology standpoint for exploring robust methods to reduce confounding between disparate groups.PubMedPubMedCentralGoogle Scholar
- 25.Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries. J Am Acad Dermatol. 2017;76(2):299–308 e216.PubMedGoogle Scholar
- 31.Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914–20.PubMedPubMedCentralGoogle Scholar
- 32.WInthrop KL, Siegel SAR, Chen L, et al. Comparative infectious risk of immunosuppressive therapies used in psoriasis. J Psoriasis Psoriatic Arthritis. 2016;2(1):7.Google Scholar
- 34.Shalom G, Naldi L, Lebwohl M, Nikkels A, de Jong EMGJ, Fakharzadeh S, et al. Biological treatment for psoriasis and the risk of herpes zoster: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Dermatolog Treat. 2018:1–20.Google Scholar
- 39.Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, et al. Ixekizumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2016;6(1):25–37.Google Scholar
- 40.Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, et al. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). J Eur Acad Dermatol Venereol. 2015;29(2):361–6.PubMedGoogle Scholar
- 44.Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–17.PubMedGoogle Scholar
- 47.Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford). 2018;57:1253–63.Google Scholar
- 53.FDA. FDA Briefing Document: Arthritis Advisory Committee Meeting. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM569317.pdf. Published 2017. Accessed February 18, 2019.